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Abstract
Background: Systemic inflammation in response to a femur fracture and the additional fixation is associated with
inflammatory complications, such as acute respiratory distress syndrome and multiple organ dysfunction syndrome.
The injury itself, but also the additional procedure of femoral fixation induces a release of pro-inflammatory
cytokines such as interleukin-6. This results in an aggravation of the initial systemic inflammatory response, and can
cause an increased risk for the development of inflammatory complications. Recent studies have shown that
administration of the serum protein C1-esterase inhibitor can significantly reduce the release of circulating pro-
inflammatory cytokines in response to acute systemic inflammation.
Objective: Attenuation of the surgery-induced additional systemic inflammatory response by perioperative
treatment with C1-esterase inhibitor of trauma patients with a femur fracture.
Methods: The study is designed as a double-blind randomized placebo-controlled trial. Trauma patients with a
femur fracture, Injury Severity Score ≥ 18 and age 18-80 years are included after obtaining informed consent. They
are randomized for administration of 200 U/kg C1-esterase inhibitor intravenously or placebo (saline 0.9%) just before
the start of the procedure of femoral fixation. The primary endpoint of the study is Δ interleukin-6, measured at t = 0,
just before start of the femur fixation surgery and administration of C1-esterase inhibitor, and t = 6, 6 hours after
administration of C1-esterase inhibitor and the femur fixation.
Conclusion: This study intents to identify C1-esterase inhibitor as a safe and potent anti-inflammatory agent, that
is capable of suppressing systemic inflammation in trauma patients. This might facilitate early total care procedures
by lowering the risk of inflammation in response to the surgical intervention. This could result in increased
functional outcomes and reduced health care related costs.
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Trauma is a major cause of morbidity and mortality in
people under the age of 50 years in the western world [1].
Death can occur as a direct result of the trauma induced
injury, or as result of a dysfunctional immune response
[2]. This excessive immune reaction is caused by the
response to tissue injury, such as seen after trauma, sur-
gery or burns. An overwhelming innate immune response
is considered to be a major risk factor in the development
of post-traumatic organ failure and sepsis. Additional
injury, induced by surgical intervention, can increase the
overall immune inflammatory reaction [3].
The lung is most often the first organ to be affected by
an exaggerated systemic immune response, which can
result in an acute respiratory distress syndrome (ARDS).
This functional impairment can be followed by other
organs, such as the liver, gastrointestinal tract and kid-
neys, leading to the so-called multiple organ dysfunction
syndrome (MODS). Presence of ARDS and MODS is a
major risk factor for mortality, long time morbidity, a
prolonged hospital stay and high health care costs [4].
One of the early and systemically released cytokines in
the early inflammatory response, is the pro-inflammatory
cytokine interleukin-6 (IL-6). Therefore, this cytokine is
widely used as an indicator for severity of the systemic
inflammatory response in clinical studies [5]. Serum IL-6
levels have been demonstrated to be closely related to the
magnitude of the injury (burden of trauma/first hit) and
to the operative procedure (second hit) [6,7]. There is a
correlation between the IL-6 concentration and the
underlying injury severity. Patients with a Injury Severity
Score (ISS) > 18 showed a more pronounced rise of IL-6
concentration compared to patients with a lower injury
severity [8].
Femur fractures, have been found associated with a pro-
found systemic inflammatory response [9-11]. Ideally, frac-
tures should be managed without a clinically important
delay to prevent excess blood loss, and preserve function.
However, in case of femur fractures, internal fixation
increases systemic inflammation [12]. In trauma patients
with an already activated inflammatory response, this
increase greatly enhances the risk of an excessive immune
response [13,14]. To address this problem, the concept of
damage control orthopedics (DCO) was developed [15,16].
This concept aims at minimizing the surgically induced
inflammatory response through limiting surgical proce-
dures [16,17]. However, DCO is a controversial approach,
because limiting surgical procedures, can lead to a reduced
quality of fracture healing, multiple interventions and a
prolonged hospital stay. This places the treating surgeon
with a difficult dilemma: early total care versus damage
control [18-20].
Therefore, there is an unmet need for limiting/pre-
venting the surgical induced inflammation, other than
limiting or delaying surgery. Until now, there is a lack
of pharmacological interventions that can reduce this
surgery induced inflammation.
A promising intervention to attenuate the systemic
innate immune response is the treatment with a high con-
centration of C1-esterase inhibitor (C1-INH) [21]. C1-
INH is an acute phase protein, produced by the liver in
response to inflammatory conditions. C1-INH is a major
inhibitor for both the complement and the contact system,
and is, therefore, an important regulator of inflammatory
reactions [22,23]. Apart from the modulation of the these
systems, C1-INH has also been shown to attenuate sys-
temic inflammation independently of the activation of
complement [24]. In fact, Dorresteijn et al showed that
administration of C1-INH, in a ‘human endotoxemia
model’, attenuates the release of pro-inflammatory cyto-
kines, including IL-6, in healthy male volunteers [21]. This
model evokes a systemic inflammatory response in the
absence of complement activation [21,25].
Aim of the study
The aim of this study is to ascertain whether administra-
tion of C1-INH in trauma patients with a femur fracture
can reduce the release of pro-inflammatory cytokines
and, therefore, will contribute to attenuation of the
inflammatory response, in response to a surgical inter-
vention (second hit). This study can provide proof of
principle for C1-INH as a potential drug for the preven-
tion of late inflammatory complications in trauma
patients.
Methods
Objectives
Attenuation of the surgery-induced additional systemic
inflammatory response by perioperative treatment with
C1-INH in trauma patients with a femur fracture. And
the effect of C1-INH on clinical outcome (e.g. ARDS,
MODS, mortality, length of hospital stay).
Study design
This clinical trial is a double blind, placebo-controlled,
randomized study, investigating the anti-inflammatory
effect of C1-INH on systemic inflammation induced by
fixation of the femur fracture in trauma patients.
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki [26] and Good Clinical
Practice Guidelines [27]. The independent ethics com-
mittee of the University Medical Centre Utrecht
(UMCU) approved the study. Written informed consent
will be obtained from all participating patients.
Study population
Seventy multi-trauma patients presented at the emergency
department of the UMCU with an ISS ≥ 18 and a femur
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Patients are eligible for the study if they meet all the inclu-
sion and none of the exclusion criteria (Table 1).
Randomization
Subjects are randomly allocated to either the C1-INH
group (intervention-group) or the placebo-group just
before the start of the surgical repair of the femur frac-
ture, using an 1:1 allocation ratio. Randomization will be
performed by the distributing pharmacy (UMCU, The
Netherlands) with the use of Design version 2.0 (Systat
S o f t w a r eI n c . ,C h i c a g o ,I L ,U S A ) .T h eC 1 - I N Ha n dp l a -
cebo solutions are prepared in identical non-transparent
infusion bags, ensuring the double-blind fashion of the
study. Patients, treating surgeons, investigators and nur-
sing personnel involved in the study will be unaware of
the randomization, and therefore, the solution applied.
Study protocol
When trauma patients meet the inclusion criteria, a first
blood sample is taken within 12 hours after trauma.
This blood sample serves as a reference for the degree
of inflammation immediately after injury. Because the
first blood sample needs to be drawn within 12 hours
after trauma, it is possible that the first sample is drawn
without the necessary informed consent and will be ana-
lyzed directly. This delayed informed consent may be
required because the inflammatory response after the
initial trauma is visible in the blood within the first 12
hours after trauma. Of course, the informed consent is
obtained as soon as possible if the patient or his/her
legal representative is able to. If no consent is obtained,
the analyzed blood and the data will be destroyed and
the patients will not receive C1-INH or placebo, because
the randomization will only take place after informed
consent is obtained.
Patients receive femur fixation surgery according to
the current protocol in the UMCU. Just after induction
of anesthesia a second blood sample will be drawn and
after this withdrawal the subject receives either C1-INH
in a dose of 200 U/kg body weight (n = 35) or placebo
(saline 0.9%, n = 35) intravenously. Two hours and six
hours after the skin incision for the surgical procedure
for femoral fixation the next blood samples are taken.
The last samples are taken 24 and 48 hours and seven
days after procedure of femoral fixation. An overview of
the time frame of the study is shown in Figure 1.
Outcome measurements
The primary outcome will be the change in serum IL-6
concentration before and after surgical repair of a femur
fracture in trauma patients in the presence or absence
o fC 1 - I N H .W eh a v ec h o s e nI L - 6a so u rp r i m a r ye n d -
point because IL-6 is one of the earliest released pro-
inflammatory cytokines after trauma, which is detectable
by multiplex assays. Several clinical studies have shown
that IL-6 is a good marker for the severity of inflamma-
tory response [5,8,10]. Because not all patients are oper-
ated at the exact same time after trauma we will use the
Δ IL-6 serum concentration (the difference in IL-6 level
between t = 0, at the start of the operation, and t = 6,
six hours after start of the operation) as our primary
endpoint. This allows the detection of the difference
between the systemic inflammation in patients treated
with or without C1-INH.
Secondary biochemical outcomes include the production
of various pro- and anti-inflammatory cytokines, cellular
activation markers and complement. Various hematologi-
cal variables and clinical chemistry measurements, such as
haemoglobin, haematocrit, leukocyte count, platelet count,
C-reactive protein and fibrinogen, are also determined.
These values reflect the clinical condition of the patient
and the severity of inflammation.
Secondary clinical outcomes include the effect of C1-
INH on the presence or absence of ARDS or MODS and
appearance of SIRS, sepsis or septic shock. To evaluate
the presence of these clinical conditions the Systemic
Response Syndrome (SIRS)-score [28] and the Sequential
Organ Failure Assessment (SOFA)-score [29] will be cal-
culated on a daily base during hospitalization of the
study subjects. The duration of admission at the intensive
care unit, duration of mechanical ventilation and total
days of hospital admission are all recorded.
Sample size calculation
The sample size calculation is based on damping of the
increase in serum IL-6 concentration by 30% in the C1-
INH group, compared to the placebo group [21,30,31].
Table 1 Patients in- and exclusion criteria
Inclusion criteria Exclusion criteria
Multi-trauma patient
ISS* ≥ 18
Femur fracture
Age 18-80 years
Informed consent
Congenital C1-inhibitor deficiency
Use of immune suppressants
Known hypersensitivity for blood
Products
Pregnancy
Fixation of the femoral fracture with external fixation or osteosynthesis
*ISS = Injury Severity Score
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a relevant decrease of IL-6 concentration of 30%
[21,30,31], 35 patients in each sample-group (C1-INH or
placebo) are needed to find a statistically significant dif-
ference (power 80%, Type 1 error rate 0.05).
Statistical analysis
The primary endpoint, the Δ IL-6, will be determined
w i t ht h eu s eo faS t u d e n t s ’ t-test. The occurrence of
inflammatory complications, such as MODS and ARDS,
will be examined with the use of a survival analysis,
such as Kaplan Meier or Cox proportional Hazard [32].
For comparisons, a t-test or Mann Whitney U-test will
be used as appropriate.
Changes over time will be analyzed using repeated
measurement analysis with time as within factor and
treatment as between factor, using Analysis of Variance.
A p-value < 0.05 is considered statistically significant.
The data will be analyzed using software programs
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism (GraphPad Software Inc., La Jolla, CA,
USA).
Interim analysis
In this study there will be two analyses performed, one
interim and the final analysis, using the O’Brien Fleming
method [33]. The alpha used for the interim analysis
will be 0.0054, and for the final analysis the alpha used
will be 0.0492.
The interim analysis will be conducted by an indepen-
dent Data Safety Monitoring Board (DSMB) after the
inclusion of 35 succeeding patients, The DSMB is com-
posed of three independent members, of which two clini-
cians and one statistician. After the interim analysis the
DSMB is able to make recommendations. In case of clear
benefit, harm or futility of the treatment, the DSMB might
decide to end the study early.
Discussion
This study represents a novel therapeutic approach for
the attenuation of the inflammatory response in trauma
patients undergoing surgical intervention. To our knowl-
edge this is the first randomized, placebo-controlled trial
examining the effect of the acute-phase protein C1-INH
on the suppression of the dysfunctional inflammatory
reaction in trauma patients during fixation of their femur
fracture. Our research, focusing on the potential thera-
peutic effect of C1-INH, could have important impact on
outcome of patients after a severe trauma.
C1-INH is proven to be effective as treatment for
improving the outcome in a variety of inflammatory dis-
ease models [22,24], including SIRS induced by infusion
of LPS [21].
The dosage C1-INH of 200 U/kg bodyweight is distinct
from earlier clinical studies. It is shown that C1-INH
synthesis increases up to 2.5 times the normal rate during
an acute phase response [34,35]. Various states of severe
inflammation, such as found during sepsis, burns and
ARDS, give a rise in the consumption of C1-INH [36].
Nuijens and colleagues also showed a reduction in func-
tional C1-INH in patients with sepsis complicated by
shock or ARDS [37]. Caliezi et al claimed that this
decrease in C1-INH levels, as result of the consumption, is
probably due to a relative deficiency in functional C1-INH
as result of enzymatic cleavage in inflamed or ischemic
tissue [22].
We also expect consumption of C1-INH in the severely
injured trauma patients in our study and thus a relative
deficiency in functional C1-INH. We hypothesize that
this consumption is mainly due to (i) the trauma itself,
(ii) the blood loss during trauma, (iii) the possible extra
blood loss during operation, and (iv) the dilution of the
blood compartment during resuscitation because of the
use of e.g. saline infusion or packed cells (erythrocytes).
To compensate this natural consumption of C1-INH in
our patients, we will administer a dose of 200 U/kg
 
Patients eligible for the 
study admitted at the 
Emergency Department are 
asked to participate 
Randomization just before 
start of the surgical repair of 
the femur fracture 
Placebo 
n  = 35 
C1-INH 
 n = 35 
Blood is drawn: 
 2, 6, 24, 48 hours and  
7 days after start of the 
operation of femur fixation 
Figure 1 Time frame.
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patient. This dose is expected to increase the circulating
C1-INH concentration at least as found under acute
phase conditions [21].
C1-INH is found to be well tolerated up to a dose of
19.000 units in patients suffering from acute myocardial
infarction [38]. In the study of Strüber et al a dose of
15.000 U, followed by 7.500 U and 5.000 U (total of 27.500
U) was administered and tolerated without any side effects
[39].
It is anticipated that this study will take three years to
complete. The study is expected to start in October of
2011 and will end after the last blood sample is drawn
from the seventieth successful included patient.
Conclusion
To the best of our knowledge this study is the first ran-
domized controlled trial designed to assess the use of
C1-INH as a possible drug for attenuation of the inflam-
matory response in trauma patients after a second hit.
And, if our hypothesis is proved correct, it will result in
increased functional outcome in trauma patients and
reduced health care related costs.
Trial status
Start trial October 2011, no patients included yet.
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